J&J bids to extend prostate cancer uses for Akeega J&J is hoping the AMPLITUDE study results will make Akeega the first drug in the PARP inhibitor class for castration-sensitive prostate cancer.

#JohnsonandJohnson's fixed-dose combination of a PARP inhibitor and anti-androgen therapy, #Akeega, has been filed for a new indication in #prostatecancer that could broaden use of the drug into hormone-sensitive disease.

pharmaphorum.com/news/jj-bids...

Johnson & Johnson's Groundbreaking Combination Therapy Offers New Hope for Prostate Cancer Patients Johnson & Johnson unveils promising results from the AMPLITUDE study, showcasing the efficacy of a PARP inhibitor combo for prostate cancer patients with specific genetic alterations.

Johnson & Johnson's Groundbreaking Combination Therapy Offers New Hope for Prostate Cancer Patients #USA #Chicago #Johnson_&_Johnson #Prostate_Cancer #AKEEGA